Carey K Anders MDAssociate Professor, Department of Medicine, Division of Hematology and Oncology, UNC-Chapel Hill, Chapel Hill, North Carolina
Carey K. Anders, MD is an Associate Professor of Medicine at the University of North Carolina (UNC) School of Medicine and an active member of the UNC Lineberger Comprehensive Cancer Center (LCCC) and co-leader of the LCCC Breast Program. As a clinician-scientist, she is Section Leader for the UNC Breast Program, Leader of the UNC breast cancer clinical trials program, and co-Director of the multi-disciplinary brain metastases clinic at UNC. Dr. Anders’ translational research program, which spans bench to bedside, focuses on the biology of triple negative breast cancer and brain metastases. She serves as the principal investigator for multiple clinical trials evaluating novel anti-cancer agents to more effectively treat patients with advanced triple negative breast cancer and brain metastases. In parallel, and supported by the UNC Chapel Hill Hematology Oncology K12, NIH/NCI K23, LCCC SPORE and Damon Runyon Clinical Investigator Award, she has developed multiple intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics in the laboratory. She is also devoted to uncovering the genetic and genomic underpinnings of triple negative breast cancer and brain metastases using Next Generation Sequencing, the focus of her American Society of Clinical Oncology Advanced Clinical Research Award. Her ultimate goal is to translate preclinical findings into rationally-designed therapeutic strategies to improve survival and enhance quality of life for the many patients facing a diagnosis of triple negative breast cancer brain metastases.